Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors.

Bošković, Lidija; Gašparić, Maja; Petković, Marija; Gugić, Damir; Belac Lovasić, Ingrid; Soldić, Željko; Petrić Miše, Branka; Dabelić, Nina; Vazdar, Ljubica; Vrdoljak, Eduard

doi:Https://doi.org/10.1016/j.breast.2016.10.018

Pregled bibliografske jedinice broj: 999245

Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors.

Bošković, Lidija; Gašparić, Maja; Petković, Marija; Gugić, Damir; Belac Lovasić, Ingrid; Soldić, Željko; Petrić Miše, Branka; Dabelić, Nina; Vazdar, Ljubica; Vrdoljak, Eduard

Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors. // The Breast, 31 (2017), 1; 16-19 doi:https://.org/10.1016/j.breast.2016.10.018 (međunarodna recenzija, članak, znanstveni)

CROSBI ID: 999245 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors.

Autori
Bošković, Lidija ; Gašparić, Maja ; Petković, Marija ; Gugić, Damir ; Belac Lovasić, Ingrid ; Soldić, Željko ; Petrić Miše, Branka ; Dabelić, Nina ; Vazdar, Ljubica ; Vrdoljak, Eduard

Izvornik
The Breast (0960-9776) 31 (2017), 1; 16-19

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Breast cancer ; Aromatase inhibitors ; Bone health ; Vitamin D ; Calcium

Sažetak
OBJECTIVES: Randomized trials involving aromatase inhibitors (AIs) in the adjuvant treatment of breast cancer patients have reported increased osteoporosis risk. Bone loss can be reduced with appropriate life style, vitamin D and calcium supplements, and with bisphosphonate therapy. The aim of this analysis was to investigate adherence to vitamin D and calcium in postmenopausal breast cancer patients receiving adjuvant non-steroidal AIs, and oncologists' adherence to the bone health guidelines. MATERIAL AND METHODS: This prospective study included 438 newly diagnosed patients and those who have already been receiving non-steroidal AIs for up to 3.5 years. Median endocrine therapy duration before recruitment in the study was 10.5 months (interquartile 4.8-26.6). RESULTS: Densitometry was performed on 142 patients (32.4%) before initiation of endocrine therapy, and on additional 38 (8.6%) patients at second study visit. Densitometry was not performed on 258 (59%) patients. Vitamin D and calcium were prescribed to 329/438 (75.1%) patients at some point during the study. Patients who took more than 80% of the prescribed dose were considered adherent. Self-reported adherence was 88.4%. Osteoporosis was diagnosed in 24 patients (5.5%) of the total study population, bearing in mind that 258/438 (59%) patients did not have densitometry. Bisphosphonates were prescribed to 54/438 (12.3%) patients, whilst only 19 (35.2%) of those had osteoporosis. CONCLUSION: In this analysis, lack of oncologists' adherence to the bone health guidelines was observed. In addition, a significant proportion of the patients did not adhere to the vitamin D and calcium.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA

Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Osijek,
KBC "Sestre Milosrdnice",
KBC Split,
Medicinski fakultet, Split,
Medicinski fakultet, Osijek,
Klinički bolnički centar Rijeka

Profili:

Eduard Vrdoljak (autor)